SCHEMBL6008117

SCHEMBL6008117

C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(C)O)[C@@]2(C)CCC(=O)C=C12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 4/20 0.76
▸ LMNA P02545 3/20 0.76
▸ MEN1 O00255 2/20 0.76
▸ KMT2A Q03164 2/20 0.76
▸ HIF1A Q16665 2/20 0.76
▸ MAPT P10636 1/20 0.76
▸ CYP2C19 P33261 1/20 0.76
▸ CYP19A1 P11511 8/20 0.70
▸ SHBG P04278 4/20 0.67
▸ PGR P06401 3/20 0.67
▸ CYP3A4 P08684 3/20 0.67
▸ ALDH1A1 P00352 3/20 0.67
▸ AR P10275 2/20 0.67
▸ ABCC4 O15439 1/20 0.67
▸ ABCB11 O95342 1/20 0.67
▸ ESR1 P03372 1/20 0.67
▸ CHRM2 P08172 1/20 0.67
▸ NR3C2 P08235 1/20 0.67
▸ CHRM1 P11229 1/20 0.67
▸ HRH2 P25021 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11521279 1.00 NR3C1 (0.76) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL6008127 1.00 NR3C1 (0.76) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL15445000 0.86 LMNA (1.00) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL22761988 0.86 LMNA (1.00) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL27035399 0.86 LMNA (1.00) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL37494 0.86 LMNA (1.00) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL13069287 0.86 LMNA (1.00) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL4877448 0.86 LMNA (1.00) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL11425597 0.86 NR3C1 (0.58) NR3C1LMNAMEN1KMT2AHIF1A
SCHEMBL11425592 0.86 NR3C1 (0.58) NR3C1LMNAMEN1KMT2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0941039-A4 TRANSDERMAL ADMINISTRATION OF MENT POPULATION COUNCIL INC (US) 2006-06-21 — — EP disclosed
US-7018648-B2 Transdermal device for administering testosterone or one of the derivatives thereof PIERRE FABRE MEDICAMENT (FR) 2006-03-28 — — US disclosed
US-20050256051-A1 Nuclear receptor-mediated introduction of a PNA into cell nuclei THE POPULATION COUNCIL, INC. (US) 2005-11-17 — — US disclosed
US-20050100586-A1 Transdermal device for administering testosterone or one of the derivatives thereof PIERRE FABRE MEDICAMENT (FR) 2005-05-12 — — US disclosed
EP-0966288-A4 ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT POPULATION COUNCIL INC (US) 2004-11-10 — — EP disclosed
EP-1178806-B1 TRANSDERMAL DEVICE FOR THE APPLICATION OF TESTOSTERONE OR ONE OF THE DERIVATIVES THEREOF PF MEDICAMENT (FR) 2004-09-01 — — EP disclosed
US-6767902-B2 Androgen as a male contraceptive and non-contraceptive androgen replacement THE POPULATION COUNCIL, INC. 2004-07-27 — — US disclosed
US-20040132698-A1 Androgen as a male contraceptive and non-contraceptive androgen replacement MOO-YOUNG ALFRED J (US) 2004-07-08 — — US disclosed
US-20040126418-A1 Transdermal administration of MENT THE POPULATION COUNCIL, INC. 2004-07-01 — — US disclosed
US-20030096739-A1 Nuclear receptor-mediated introduction of a PNA into cell nuclei POPULATION COUNCIL, INC., THE 2003-05-22 — — US disclosed
US-20020193359-A1 Administering to a non-sterile male subject a predetermined amount of an androgen which is sufficient to render male subject reversibly sterile for a predetermined period of time POPULATION COUNCIL, INC., THE 2002-12-19 — — US disclosed
EP-1178806-A1 TRANSDERMAL DEVICE FOR THE APPLICATION OF TESTOSTERONE OR ONE OF THE DERIVATIVES THEREOF PIERRE FABRE MEDICAMENT (FR) 2002-02-13 — — EP disclosed
US-20020012694-A1 TRANSDERMAL ADMINISTRATION OF MENT POPULATION COUNCIL, INC., THE, A CORP. OF NY 2002-01-31 — — US disclosed
WO-2000071133-A1 TRANSDERMAL DEVICE FOR THE APPLICATION OF TESTOSTERONE OR ONE OF THE DERIVATIVES THEREOF PIERRE FABRE MEDICAMENT (FR) 2000-11-30 — — WO disclosed
EP-0966288-A1 ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT THE POPULATION COUNCIL, INC. (US) 1999-12-29 — — EP disclosed
EP-0941039-A1 TRANSDERMAL ADMINISTRATION OF MENT THE POPULATION COUNCIL, INC. (US) 1999-09-15 — — EP disclosed
WO-1999013883-A1 ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT THE POPULATION COUNCIL, INC. (US) 1999-03-25 — — WO disclosed
WO-1999013812-A1 TRANSDERMAL ADMINISTRATION OF MENT THE POPULATION COUNCIL, INC. (US) 1999-03-25 — — WO disclosed
US-5342834-A Administering testosterone derivatives THE POPULATION COUNCIL, INC. (US) 1994-08-30 — — US disclosed
US-4160027-A OXYTOCICS, 4A,5A-EPOXY-2A-CYANO-3-OXOSTEROIDES, STEROIDO(2,3-O)ISOOXAZOLES STERLING DRUG INC. (US) 1979-07-03 — — US disclosed
Send feedback